LSV Asset Management Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

LSV Asset Management raised its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,480,563 shares of the specialty pharmaceutical company’s stock after buying an additional 99,705 shares during the quarter. LSV Asset Management owned about 3.93% of Jazz Pharmaceuticals worth $264,750,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in JAZZ. Victory Capital Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 4.3% in the fourth quarter. Victory Capital Management Inc. now owns 136,589 shares of the specialty pharmaceutical company’s stock worth $16,800,000 after purchasing an additional 5,614 shares during the last quarter. Private Advisor Group LLC raised its stake in shares of Jazz Pharmaceuticals by 49.2% in the fourth quarter. Private Advisor Group LLC now owns 2,967 shares of the specialty pharmaceutical company’s stock worth $365,000 after purchasing an additional 979 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth $3,663,000. Boston Partners grew its holdings in shares of Jazz Pharmaceuticals by 21.6% in the fourth quarter. Boston Partners now owns 12,069 shares of the specialty pharmaceutical company’s stock worth $1,484,000 after acquiring an additional 2,141 shares during the period. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of Jazz Pharmaceuticals by 40.4% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 7,601 shares of the specialty pharmaceutical company’s stock worth $935,000 after acquiring an additional 2,186 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock traded down $1.25 during trading hours on Friday, hitting $107.14. The company’s stock had a trading volume of 1,160,096 shares, compared to its average volume of 692,521. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The company has a market cap of $6.76 billion, a PE ratio of 22.09, a PEG ratio of 1.45 and a beta of 0.57. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $137.57. The business has a 50 day moving average price of $109.75 and a two-hundred day moving average price of $112.24.

Analyst Ratings Changes

JAZZ has been the subject of several research analyst reports. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a report on Monday, August 19th. Cantor Fitzgerald reissued an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Needham & Company LLC cut their price target on Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Finally, Morgan Stanley cut their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.